ATE154758T1 - Levobupivacain nützlich zur behandlung von chronischen schmerzen - Google Patents

Levobupivacain nützlich zur behandlung von chronischen schmerzen

Info

Publication number
ATE154758T1
ATE154758T1 AT94929595T AT94929595T ATE154758T1 AT E154758 T1 ATE154758 T1 AT E154758T1 AT 94929595 T AT94929595 T AT 94929595T AT 94929595 T AT94929595 T AT 94929595T AT E154758 T1 ATE154758 T1 AT E154758T1
Authority
AT
Austria
Prior art keywords
pct
chronic pain
levobupivacain
useful
treating chronic
Prior art date
Application number
AT94929595T
Other languages
English (en)
Inventor
Hazel Judith Bardsley
Laurence Mather
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10743430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE154758(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Application granted granted Critical
Publication of ATE154758T1 publication Critical patent/ATE154758T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
AT94929595T 1993-10-13 1994-10-13 Levobupivacain nützlich zur behandlung von chronischen schmerzen ATE154758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939321061A GB9321061D0 (en) 1993-10-13 1993-10-13 Analgestic agent and its use

Publications (1)

Publication Number Publication Date
ATE154758T1 true ATE154758T1 (de) 1997-07-15

Family

ID=10743430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929595T ATE154758T1 (de) 1993-10-13 1994-10-13 Levobupivacain nützlich zur behandlung von chronischen schmerzen

Country Status (16)

Country Link
US (1) US5955479A (de)
EP (1) EP0723444B1 (de)
JP (1) JPH09503777A (de)
KR (1) KR100343314B1 (de)
CN (1) CN1074919C (de)
AT (1) ATE154758T1 (de)
AU (1) AU692477B2 (de)
CA (1) CA2173208C (de)
DE (1) DE69403969T2 (de)
DK (1) DK0723444T3 (de)
ES (1) ES2105766T3 (de)
GB (1) GB9321061D0 (de)
GR (1) GR3024787T3 (de)
HK (1) HK1006421A1 (de)
NO (1) NO309304B1 (de)
WO (1) WO1995010276A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU704806B2 (en) * 1995-04-13 1999-05-06 Darwin Discovery Limited Levobupivacaine and its use as an anaesthetic in pregnant women
GB9704349D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
GB9704370D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
GB9704352D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
KR20010022041A (ko) * 1997-07-21 2001-03-15 클래스 빌헬름슨 뇌 신경혈관 장애 및 근육성 두통 억제용 조성물, 키트 및방법
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
BR9802537A (pt) * 1997-07-22 1999-07-20 Darwin Discovery Ltd Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
ATE535232T1 (de) 1997-09-18 2011-12-15 Pacira Pharmaceuticals Inc Retardierte freisetzung liposomaler anesthetischer zusammensetzungen
IL135989A0 (en) 1997-11-14 2001-05-20 Skyepharma Inc Processes for the production of multivesicular liposomes
CA2308495C (en) * 1997-11-19 2009-01-06 Darwin Discovery Limited Anaesthetic formulation
ES2325141T3 (es) 1998-07-17 2009-08-26 Pacira Pharmaceuticals, Inc. Composiciones biodegradables para la liberacion controlada de sustancias encapsuladas.
BR0002246A (pt) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
EP1395243A2 (de) * 2001-05-31 2004-03-10 SkyePharma Inc. Verkapselung von nanosuspensionen in liposomen und mikrosphärulen
IL162001A0 (en) 2001-11-14 2005-11-20 Alza Corp Catheter injectable depot compositions and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
NZ537953A (en) 2002-07-31 2007-02-23 Alza Corp Injectable multimodal polymer depot compositions and uses thereof
AU2002359397B2 (en) 2002-07-31 2009-01-29 Durect Corporation Injectable depot compositions and uses thereof
ES2388355T3 (es) 2006-11-03 2012-10-11 Durect Corporation Sistemas de suministro transdémico que comprenden bupivacaína
DE102008037682A1 (de) * 2008-08-14 2010-04-08 Strackharn, Klaus, Dr.med. Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
EP3558279A4 (de) * 2016-12-26 2020-12-02 Cellix Bio Private Limited Zusammensetzungen und verfahren zur behandlung chronischer schmerzen
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
GB2627096A (en) 2021-10-14 2024-08-14 Pacira Pharmaceuticals Inc Bupivacaine multivesicular liposome formulations and uses thereof
US12070454B1 (en) 2022-05-05 2024-08-27 Pfof Llc Anesthetic nerve block and method
CA3251322A1 (en) 2022-05-05 2023-11-09 Pfof Llc ANESTHETIC NERVE BLOCK AND PROCEDURE
US12280149B1 (en) 2024-05-20 2025-04-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide
HK1006420A1 (en) * 1993-10-13 1999-02-26 Chiroscience Limited Analgesic agent and its use
ITTO20010597A1 (it) * 2001-06-20 2002-12-20 Plaset Spa Pompa per liquidi, in particolare pompa centrifuga per apparecchi elettrodomestici.

Also Published As

Publication number Publication date
DE69403969T2 (de) 1997-11-20
KR100343314B1 (ko) 2003-02-19
HK1006421A1 (en) 1999-02-26
EP0723444A1 (de) 1996-07-31
GB9321061D0 (en) 1993-12-01
CA2173208A1 (en) 1995-04-20
CA2173208C (en) 2007-01-30
EP0723444B1 (de) 1997-06-25
CN1074919C (zh) 2001-11-21
NO961478L (no) 1996-06-11
WO1995010276A1 (en) 1995-04-20
CN1133009A (zh) 1996-10-09
DE69403969D1 (de) 1997-07-31
AU692477B2 (en) 1998-06-11
NO309304B1 (no) 2001-01-15
US5955479A (en) 1999-09-21
GR3024787T3 (en) 1998-01-30
ES2105766T3 (es) 1997-10-16
NO961478D0 (no) 1996-04-12
AU7859394A (en) 1995-05-04
DK0723444T3 (da) 1997-12-29
JPH09503777A (ja) 1997-04-15

Similar Documents

Publication Publication Date Title
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
DE69333014D1 (de) Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE142875T1 (de) Methode zur behandlung von haarausfall
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
DE69630055D1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
DE69627298D1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EEIH Change in the person of patent owner